Explore the case reports, reviews, diagnostic studies, and laboratory research that shape current understanding of Perry syndrome. Each summary separates the findings from the limits of the evidence.
Research
The research behind Perry syndrome
Read the studies that shape what clinicians know about Perry syndrome. Each summary explains the findings, why they matter, and what the study cannot prove.
Featured family report · Colombia · 2014
A Colombian family with 11 reportedly affected members
A 2014 report documented Latin America’s first genetically confirmed case of Perry syndrome. It described one 56-year-old Colombian woman in detail and recorded ten additional maternal relatives with similar symptoms, for 11 reportedly affected family members in all.
clinically detailed patient
1
additional relatives in the family history
10
reportedly affected family members in total
11
published follow-up after diaphragm pacing
2 years
The reported family history
The paper states that all ten relatives died of respiratory insufficiency, but it gives no individual records, genetic results, ages, or treatment outcomes for them.
1mother
4maternal uncles
2sisters
3maternal cousins
What the genetic result means
DCTN1 provides instructions for part of the dynactin complex, which helps move materials inside nerve cells. Perry syndrome usually follows an autosomal-dominant pattern. A genetics professional should interpret a specific result and discuss testing choices with each family.
DCTN1 c.211G>A (p.Gly71Arg / p.G71R)
The index patient’s published course
01
Movement, mood, and weight changes
She had a two-year history of parkinsonism, severe depression and anxiety, and a 15-kilogram weight loss over six months. Her movement findings included reduced facial expression, rigidity, and tremor.
02
Acute breathing deterioration
She was admitted with rapidly worsening respiratory insufficiency. Testing showed dangerous carbon-dioxide retention and supported a central, brain-driven cause of hypoventilation.
03
Genetic confirmation
Testing identified the DCTN1 change c.211G>A (p.Gly71Arg), also written p.G71R, confirming Perry syndrome in the index patient.
04
Escalating respiratory support
Noninvasive support had not succeeded. A tracheostomy and mechanical ventilation were required, and attempts to wean her from the ventilator were unsuccessful.
05
Diaphragm pacing
Her multidisciplinary team implanted a bilateral system that stimulated the phrenic nerves to activate the diaphragm. The procedure had a mild right hemothorax and air under the skin as reported complications.
06
Two-year report
Felipe Pretelt, Camilo Castañeda Cardona, Pawel Tacik, Owen A. Ross, and Zbigniew K. Wszolek reported a functioning pacer, independence in everyday life, and no acute respiratory-failure episodes during follow-up. Pneumonia still occurred occasionally and was treated with antibiotics.
Why the report matters
The case shows that life-threatening breathing failure can dominate the illness even when movement disability is comparatively mild. It also shows how a correct genetic diagnosis can help neurological, respiratory, and surgical teams consider highly specialized support.
What we know
What the research tells us
Taken together, these studies show a recognizable but variable condition. They also make clear that most evidence still comes from case reports, small series, and expert reviews.
01
Recognize a pattern, not a checklist
Perry syndrome most often combines parkinsonism, depression or apathy, unexpected weight loss, and central hypoventilation. The complete four-feature pattern may not be present at diagnosis, and presentations can differ substantially even within one family.
02
Diagnosis joins clinical and genetic evidence
A three-generation family history, movement and mood assessment, weight and swallowing review, and active respiratory evaluation all matter. A disease-associated DCTN1 variant can confirm the diagnosis in the right clinical setting, but not every DCTN1 variant causes Perry syndrome.
03
Breathing surveillance is central
Central hypoventilation is a leading threat and can first appear during sleep, late in the illness, or unexpectedly early. The recent reviews support specialist-directed sleep and respiratory assessment even when daytime breathing symptoms are not obvious.
04
Care is supportive and individualized
There is no approved disease-modifying treatment. Published care includes symptom-directed movement and psychiatric treatment, nutrition and swallowing support, and specialist-selected noninvasive or invasive ventilation. Responses and complications vary.
05
Historical averages do not predict one person
Older compilations placed average onset near age 49 and average reported duration near five years, but the groups were small and selected. Variants, family modifiers, respiratory support, and individual care can change the course substantially.
06
The biology points to TDP-43 and cellular transport
Perry-associated DCTN1 changes affect the dynactin transport system, and brain tissue shows a distinctive TDP-43 proteinopathy. New RNA findings may guide future biomarkers or therapies, but they have not yet produced a clinical test or treatment.
From the 2026 management review
A proposed five-stage framework
Tomasz Chmiela and Zbigniew Wszolek proposed this framework from published reports and clinical experience to support research and care discussions. It is not a validated scale and should not be used to predict an individual outcome.
1
Stage I · Asymptomatic
A pathogenic or likely pathogenic DCTN1 variant is present without symptoms.
2
Stage II · Early symptomatic
Parkinsonism, mild cognitive change, or depression is present, but the person remains fully independent and symptoms are adequately controlled when treatment is needed.
3
Stage III · Mild
Symptoms affect daily living and require treatment, without hypoventilation, weight loss, or swallowing difficulty.
4
Stage IV · Moderate
Daily living is affected and at least one of hypoventilation, weight loss, or swallowing difficulty is present.
5
Stage V · Severe
The person needs help with all daily functions, or requires ventilatory support or tube feeding.
!Proposed in 2026; not yet validated in a patient cohort and not a formal standard of care.
A 2025 study of seven Perry syndrome brains found eight TDP-43-regulated RNA changes in the caudate nucleus, while only UNC13A reached significance in the substantia nigra despite similar abnormal TDP-43 burden. An altered HDGFL2 protein was also elevated in the caudate nucleus.
Reduced orexin signals a possible sleep and arousal pathway
Postmortem findings published in 2017 point to reduced orexin immunoreactivity in the nucleus basalis of Meynert in three Perry syndrome cases compared with controls. Two of the three had sleep apnea confirmed by polysomnography. Across the pooled Perry syndrome and FTLD-MND analysis, the association between orexin and TDP-43 burden did not reach statistical significance.
These small postmortem studies identify mechanisms and research targets. They do not provide a diagnostic blood or spinal-fluid test, prove what caused a person’s symptoms, or establish a treatment.
Read the studies
Perry syndrome research, explained
For each study, we explain the main findings, why they matter, and what the study cannot tell us.
2026Current management review
A 2026 overview of care and research directions
Current advances in the clinical management of Perry syndrome: is there hope for the future?
Care remains supportive and highly individualized. The 2026 overview brings together recognition, diagnosis, respiratory monitoring, symptom management, a proposed staging system, and emerging research; its literature search runs through September 2025 and finds more than 160 reported cases in a still-small evidence base.
Read findings, limits, and relevance+
Key findings
No approved disease-modifying treatment or active Perry-specific disease-modifying drug trial was identified at the review’s cutoff.
Polysomnography and respiratory assessment are emphasized because central hypoventilation can be subtle, sudden, and life-threatening.
The paper proposes five clinical stages and identifies TDP-43, cryptic splicing, RNA toxicity, and axonal transport as future research targets.
Important limitations
As an expert narrative review, it is neither a treatment guideline nor a controlled trial. Most Perry-specific management evidence comes from case reports and small series, and the proposed stages remain unvalidated.
Why it matters
It is the strongest uploaded source for current family-facing care context and for separating available supportive care from experimental ideas.
2025Mechanistic brain research
TDP-43 changes RNA differently across brain regions
TDP-43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP-43 Proteinopathies
RNA processing differs between the caudate nucleus and substantia nigra when normal TDP-43 function is lost. Pickles, Gonzalez Bejarano, Narayan, and their colleagues examined postmortem tissue from seven Perry syndrome cases, 12 FTLD-TDP cases, and 11 controls for hidden, or cryptic, RNA sequences entering mature messages.
Read findings, limits, and relevance+
Key findings
Abnormal phosphorylated TDP-43 accumulated in both Perry syndrome regions, at lower levels than FTLD but above controls.
Eight selected cryptic or skiptic RNA targets were elevated in the caudate nucleus; only UNC13A reached significance in the substantia nigra.
HDGFL2 cryptic protein was elevated in the caudate nucleus but not the substantia nigra.
Cell composition and normal transcript abundance helped explain the regional difference, but did not fully account for it.
Important limitations
The study was postmortem and cross-sectional, involved seven Perry syndrome brains, examined two regions with bulk tissue, and had RNA-quality exclusions. It had no independent Perry replication group, biofluid validation, or treatment experiment.
Why it matters
It strengthens the evidence that TDP-43 loss of function matters in Perry syndrome and identifies candidate biomarkers and therapeutic targets for future study. These are not tools ready for clinical use.
2021Worldwide cases and literature review
Clinical, pathological, and genetic variability across families
Clinical, pathological and genetic characteristics of Perry disease: new cases and literature review
By June 2021, the published record included 31 families and 160 reported cases. Six people from New Zealand, Poland, and Colombia were newly described or updated, alongside clinical observations, genetic findings, and a Colombian autopsy.
Read findings, limits, and relevance+
Key findings
Presentations varied from respiratory failure as a major early event to depression, parkinsonism, weight loss, autonomic symptoms, swallowing difficulty, and nighttime breathing disturbance.
Respiratory features were reported in 27 of 31 families and weight loss in 23, but neither every symptom nor a fixed sequence occurred in everyone.
Levodopa response ranged from limited to meaningful, with motor fluctuations and dyskinesia in some reports.
The autopsy supported a distinctive pallidonigral pattern with TDP-43 inclusions in basal ganglia and brainstem regions.
Important limitations
The totals were a historical literature snapshot, not a prevalence study. Many data came from retrospective reports with inconsistent assessments, and treatment observations were uncontrolled.
Why it matters
It demonstrates why a missing feature should not automatically rule out the diagnosis and why respiratory, psychiatric, genetic, nutrition, and movement care must be coordinated.
2020Individual case report
Depression and fainting preceded a genetic answer
Perry syndrome: a case of atypical parkinsonism with confirmed DCTN1 mutation
A New Zealand woman first presented at age 50 with recurrent fainting, worsening depression, orthostatic symptoms, and disequilibrium. Two years later she developed tremor, marked facial masking, rigidity, a postural blood-pressure drop, and a nine-kilogram weight loss.
Read findings, limits, and relevance+
Key findings
A strong maternal history of respiratory deaths and an aunt with genetically confirmed Perry syndrome prompted testing.
The patient carried DCTN1 c.233A>G (p.Y78C). Overnight oximetry did not show hypoventilation at that assessment.
At six months, McManus, Poke, Phillips, and Asztely reported improvement in movement, facial expression, mood, and weight after individualized symptom and nutrition treatment.
Important limitations
This was one patient with short follow-up, no control, partly subjective outcomes, and an uncertain relationship to a previously reported New Zealand pedigree.
Why it matters
It shows how mood and autonomic symptoms may precede a recognizable movement disorder, and that a normal early overnight oximetry result does not erase the need for ongoing clinical judgment.
2020Related movement-disorders genetics
Why ancestry and representative genetic studies matter
Prevalence of GBA p.K198E mutation in Colombian and Hispanic populations
Context only: not Perry syndrome evidence
The focus is GBA p.K198E in Parkinson disease, not Perry syndrome. The cohort included 142 Colombian Parkinson disease patients, 58 Colombian controls, and 67 Hispanic-American Parkinson disease patients.
Read findings, limits, and relevance+
Key findings
GBA p.K198E was found in three Colombian Parkinson disease participants (2.1%) and one Colombian control (1.7%), with no carriers in the Hispanic-American group.
The variant was not significantly associated with Parkinson disease risk in this cohort, and the confidence intervals were very wide.
Tipton, Soto-Beasley, Walton, and their colleagues called for larger studies that represent different Latin American regions and ancestries.
Important limitations
Sampling was opportunistic, only four carriers were found, the control group was small, and only one selected GBA variant was tested.
Why it matters
Its relevance is methodological: genetic results from one population or region may not generalize to another. It does not show that GBA causes, modifies, diagnoses, or treats Perry syndrome.
2017Clinical and genetic review
Perry syndrome within the wider DCTN1 disease spectrum
DCTN1-related neurodegeneration: Perry syndrome and beyond
Perry syndrome sits within a broader spectrum of DCTN1-related neurodegeneration. Combining published reports with Canadian, Polish, and Brazilian families, the 2017 review covered 23 families and documented presentations beyond the classic pattern.
Read findings, limits, and relevance+
Key findings
Classic features can coexist with vertical gaze problems, falls, frontal behavior or cognition changes, autonomic symptoms, and PSP- or FTD-like presentations.
Perry-associated changes cluster in or near the CAP-Gly microtubule-binding region of dynactin, but DCTN1 variants elsewhere can produce different neurological disorders.
Brain pathology centers on substantia nigra and basal-ganglia or brainstem TDP-43 changes rather than the typical Lewy-body pattern of Parkinson disease.
No specific MRI pattern reliably identifies Perry syndrome, and Perry-like phenotypes can have other genetic causes.
Important limitations
The family counts and natural-history estimates reflect literature available in 2017. Ascertainment favored affected families, variant evidence varied, and the statistics cannot estimate an individual carrier’s penetrance or course.
Why it matters
It supports careful variant interpretation: a DCTN1 result, its location and classification, family segregation, and the person’s clinical pattern must be assessed together.
2017Exploratory pathology study
A possible orexin link to sleep and arousal
Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy
Reduced orexin-containing nerve fibers in a brain region involved in arousal point to a possible sleep-related pathway. The postmortem comparison examined the nucleus basalis of Meynert in three Perry syndrome cases, five FTLD-MND cases, five multiple system atrophy cases, and five controls.
Read findings, limits, and relevance+
Key findings
Orexin immunoreactivity was significantly lower in the Perry syndrome and multiple system atrophy groups than in controls.
All three Perry syndrome brains had TDP-43 lesions in the sampled region. Across the pooled Perry syndrome and FTLD-MND cases, the association between orexin reduction and TDP-43 score did not reach statistical significance.
Two of the three Perry syndrome cases had sleep apnea confirmed by polysomnography.
Important limitations
Only three Perry syndrome brains were studied. Sleep histories were retrospective and incomplete, the orexin-producing lateral hypothalamus was unavailable, and the sampling method could not quantify the entire region stereologically.
Why it matters
It offers a biologic clue for future sleep and arousal research, but it does not establish an orexin test, a causal pathway, or an orexin-directed treatment for Perry syndrome.
2014Three-family clinical and laboratory study
New Zealand, United States, and Colombian families
Three families with Perry syndrome from distinct parts of the world
Perry syndrome was documented across families in New Zealand, the United States, and Colombia, with three clinically studied probands and 17 additional symptomatic relatives identified through family histories. Sequencing centered on the probands, with one Colombian daughter also tested; laboratory assays evaluated how the identified variants affected microtubule binding.
Read findings, limits, and relevance+
Key findings
The New Zealand family carried DCTN1 p.Y78C; the United States and Colombian families carried p.G71R.
All three probands had the characteristic movement, mood, weight, and respiratory pattern, while dopaminergic response was partial in the two treated probands.
Both variants reduced p150Glued microtubule binding in overexpressing cell assays, supporting pathogenicity.
Respiratory insufficiency drove most reported deaths; the Colombian proband’s diaphragm-pacing outcome was followed for two and a half years.
Important limitations
This was an observational three-proband series with retrospective family information, nonrandomized care, one pacing recipient, and functional assays in engineered HEK293E cells rather than patient neurons. Most additional affected relatives were reported through family history rather than individually genetically confirmed.
Why it matters
It helped establish global distribution, the importance of respiratory evaluation, and functional evidence for two disease-associated DCTN1 variants.
2012Historical teaching and discovery context
From the first family to the DCTN1 discovery
Perry Syndrome: Clinical, Genetic, and Pathological Aspects
The 2012 Bogotá Grand Rounds packet preserves an educational snapshot of the field rather than a standalone journal article. It combines a 2010 GeneReviews overview with pages from the 2009 Nature Genetics paper that identified disease-segregating DCTN1 variants.
Read findings, limits, and relevance+
Key findings
The first family was described in 1975, and an international consortium later assembled clinical data and DNA from families in several countries.
The 2009 discovery study examined eight families and identified five substitutions in the CAP-Gly region: G71R, G71E, G71A, T72P, and Q74P.
The reported variants were absent from 949 unrelated controls and 475 additional familial-parkinsonism probands.
Laboratory work showed reduced microtubule binding and altered dynactin distribution, supporting a disease mechanism involving intracellular transport.
Important limitations
The lecture’s case counts, country percentages, medication statements, and older diagnostic framework are dated and should not be used as current guidance. The linked record is the embedded 2009 discovery paper, not the lecture itself.
Why it matters
It preserves the history of international collaboration and the genetic discovery that made molecular confirmation and modern family research possible.
More Perry syndrome studies
Original articles and reviews that helped shape current understanding of Perry syndrome.